



#11/1637  
7/8/03  
Docket No. CDS-2323

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : John W. Sutherland

Serial No. : 09/877,748

Art Unit: 1637

Filed : June 11, 2001

Examiner: Cynthia Wilder

For : DETECTING NUCLEIC ACID DETECTION SEQUENCES

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 On:

July 1, 2003

(Date)

Todd F. Volyn

Name of applicant, assignee, or Registered Representative

*Todd F. Volyn*  
(Signature)

July 1, 2003

(Date of Signature)

RECEIVED  
JUL 07 2003  
TECH CENTER 1600/2900

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 226313-1450

**RESPONSE TO OFFICE ACTION**

Dear Sir:

This communication is responsive to the Office Action dated June 10, 2003 that relates to the application noted above.

The Examiner has levied a restriction requirement that divides the application into three potential groups. She has further restricted the last group (Group III) into different inventions for each recited species of nucleic acid recited in the claims.

Applicant elects Group I with traverse.

Group I inventions are directed to methods for detecting nucleic acid mutations (e.g., deletions). Group II inventions are directed to methods for quantitating nucleic acids having deletions. The Examiner maintains these two groups of inventions are unrelated and that they have different modes of operation, different functions, or different effects. One cannot quantitate a nucleic acid with a deletion without detecting it. Indeed, quantitation, in this context, is detection with numerical specificity and deletions are mutations. Accordingly, it cannot be fairly said that Group I and Group II claims are drawn to unrelated processes such that restriction is required.

With respect to the sequences recited in Group III, the Examiner is respectfully reminded that it is the position of the PTO that:

"to further aid the biotechnology industry in protecting its intellectual property without creating an undue burden on the Office, the Commissioner has decided *sua sponte* to partially waive the requirements of 37 CFR 1.141 *et seq.*, and permit a reasonable number of such nucleotide sequences in a single application." MPEP 803.04


Ordinarily, the PTO considers at least ten sequences to be a reasonable number. In this case, the recited sequences are primers and probes (two primers and one probe per target). Thus, the total of 22 claimed short sequences are well within the guidelines set by the Commissioner. In any case, including all of the claimed inventions together does not pose a serious burden on the Examiner since searching within any of the fields of the various Groups of inventions will require a search of every field among the three Groups anyway.

The restriction requirement should be removed entirely. Even if this does not occur, Group I and Group II inventions should be prosecuted together. The Examiner is thus respectfully solicited to take such action.

Please charge any fees which may be required for this submission to Johnson & Johnson Deposit Account No.

10-0750/CDS-232/TFV.

Respectfully submitted,

  
\_\_\_\_\_  
Todd F. Volyn  
Attorney for Applicants  
Reg. No. 37,463

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
Tel: 732 524-6202  
Dated: July 1, 2003